Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Fine SW, Trpkov K, Amin MB, Algaba F, Aron M, Baydar DE, et al. Practice patterns related to prostate cancer grading: results of a 2019 Genitourinary Pathology Society clinician survey. Urol Oncol. 2021;39(5):295.e1-295.e8.

Hwang I, Tang D, Paik J. Oxidative stress sensing and response in neural stem cell fate. Free Radic Biol Med. 2021;169:74-83.

Liu D, Augello MA, Grbesa I, Prandi D, Liu Y, Shoag JE, et al. Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. J Clin Invest. 2021;131(10).

Stern ES, Siddiqui MT. Nuclear hypochromasia: Shedding light on the "lightness" of high-grade urothelial carcinoma. Diagn Cytopathol. 2021;49(9):1032-1035.

Khan U, Ho K, Hwang EK, Peña C, Brouwer J, Hoffman K, et al. Impact of Use of Antibiotics on Response to Immune Checkpoint Inhibitors and Tumor Microenvironment. Am J Clin Oncol. 2021;44(6):247-253.

Wang X, Gkrouzman E, Andrade DC, Andreoli L, Barbhaiya M, H Belmont M, et al. COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION). Lupus. 2021;30(14):2276-2285.

Showers CR, Nuovo GJ, Lakhanpal A, Siegel CH, Aizer J, Elreda L, et al. A Covid-19 Patient with Complement-Mediated Coagulopathy and Severe Thrombosis. Pathobiology. 2021;88(1):28-36.

Deng J, Thennavan A, Dolgalev I, Chen T, Li J, Marzio A, et al. ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer. Nat Cancer. 2021;2(5):503-514.

Adib E, Nassar AH, Akl EW, Alaiwi SA, Nuzzo PV, Mouhieddine TH, et al. CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. Clin Cancer Res. 2021;27(14):4025-4035.

Pappa T, Ahmadi S, Marqusee E, Johnson HL, Nehs MA, Cho NL, et al. Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in BRAFV600E -Driven Papillary Thyroid Cancer Patients. Clin Cancer Res. 2021;27(15):4256-4264.